Magnetic resonance spectroscopy in mild cognitive impairment: Systematic review and meta-analysis

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 10, 2013, Pages 2571-2586

  Tumati, Shankar ^a   Martens, Sander ^a   Aleman, André ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Alzheimer's Disease (AD); Choline (Cho); Creatine (Cr); Hippocampus; Magnetic Resonance Spectroscopy (MRS); Mild Cognitive Impairment (MCI); Myo inositol (mI); N Acetyl Aspartate (NAA); Paratrigonal white matter; Posterior cingulate

Indexed keywords

CHOLINE; CREATINE; INOSITOL; N ACETYLASPARTIC ACID;

BRAIN METABOLISM; EARLY DIAGNOSIS; ENTORHINAL CORTEX; HIPPOCAMPUS; HUMAN; META ANALYSIS; METABOLITE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARIETAL CORTEX; PARIETAL LOBE; POSTERIOR CINGULATE; PREDICTIVE VALUE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RELIABILITY; REVIEW; SYSTEMATIC REVIEW; TEMPORAL CORTEX; THALAMUS; WHITE MATTER;

ALZHEIMER'S DISEASE (AD); CHOLINE (CHO); CREATINE (CR); HIPPOCAMPUS; MAGNETIC RESONANCE SPECTROSCOPY (MRS); MILD COGNITIVE IMPAIRMENT (MCI); MYO-INOSITOL (MI); N-ACETYL ASPARTATE (NAA); PARATRIGONAL WHITE MATTER; POSTERIOR CINGULATE;

ASPARTIC ACID; CHOLINE; CREATINE; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MILD COGNITIVE IMPAIRMENT;

EID: 84889666950     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.08.004     Document Type: Review

References (94)

1. Ackl N., Ising M., Schreiber Y.A., Atiya M., Sonntag A., Auer D.P. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neuroscience Letters 2005, 384:23-28.
2. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia: the Journal of the Alzheimer's Association 2011, 7:270-279.
3. Alger J.R. Quantitative proton magnetic resonance spectroscopy and spectroscopic imaging of the brain: a didactic review. Topics in Magnetic Resonance Imaging: TMRI 2010, 21:115-128.
4. Angelie E., Bonmartin A., Boudraa A., Gonnaud P.M., Mallet J.J., Sappey-Marinier D. Regional differences and metabolic changes in normal aging of the human brain: proton MR spectroscopic imaging study. AJNR. American Journal of Neuroradiology 2001, 22:119-127.
5. Block W., Traber F., Flacke S., Jessen F., Pohl C., Schild H. In-vivo proton MR-spectroscopy of the human brain: assessment of N-acetylaspartate (NAA) reduction as a marker for neurodegeneration. Amino acids 2002, 23:317-323.
6. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 1991, 82:239-259.
7. Catani M., Cherubini A., Howard R., Tarducci R., Pelliccioli G.P., Piccirilli M., Gobbi G., Senin U., Mecocci P. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 2001, 12:2315-2317.
8. Chantal S., Braun C.M., Bouchard R.W., Labelle M., Boulanger Y. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Research 2004, 1003:26-35.
9. Chao L.L., Mueller S.G., Buckley S.T., Peek K., Raptentsetseng S., Elman J., Yaffe K., Miller B.L., Kramer J.H., Madison C., Mungas D., Schuff N., Weiner M.W. Evidence of neurodegeneration in brains of older adults who do not yet fulfill MCI criteria. Neurobiology of Aging 2010, 31:368-377.
10. Cohen J. A power primer. Psychological Bulletin 1992, 112:155-159.
11. De Souza A.S., De Oliveira-Souza R., Moll J., Tovar-Moll F., Andreiuolo P.A., Bottino C.M.C. Contribution of 1H spectroscopy to a brief cognitive-functional test battery for the diagnosis of mild Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2011, 32:351-361.
12. De Stefano N., Matthews P.M., Arnold D.L. Reversible decreases in N-acetylaspartate after acute brain injury. Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 1995, 34:721-727.
13. Didic M., Ranjeva J.P., Barbeau E., Confort-Gouny S., Fur Y.L., Felician O., Mancini J., Poncet M., Ceccaldi M., Cozzone P. Impaired visual recognition memory in amnestic mild cognitive impairment is associated with mesiotemporal metabolic changes on magnetic resonance spectroscopic imaging. Journal of Alzheimer's Disease: JAD 2010, 22:1269-1279.
14. Duara R., Loewenstein D.A., Greig M.T., Potter E., Barker W., Raj A., Schinka J., Borenstein A., Schoenberg M., Wu Y., Banko J., Potter H. Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry 2011, 19:951-960.
15. Duarte J.M., Lei H., Mlynarik V., Gruetter R. The neurochemical profile quantified by in vivo 1H NMR spectroscopy. NeuroImage 2012, 61:342-362.
16. Dubois B., Albert M.L. Amnestic MCI or prodromal Alzheimer's disease?. Lancet Neurology 2004, 3:246-248.
17. Falini A., Bozzali M., Magnani G., Pero G., Gambini A., Benedetti B., Mossini R., Franceschi M., Comi G., Scotti G., Filippi M. A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment. NeuroImage 2005, 26:1159-1163.
18. Fayed N., Davila J., Oliveros A., Castillo J., Medrano J.J. Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. Academic Radiology 2008, 15:1089-1098.
19. Fayed N., Modrego P.J., Rojas-Salinas G., Aguilar K. Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study. American Journal of Alzheimer's Disease and Other Dementias 2011, 26:450-456.
20. Fisher S.K., Novak J.E., Agranoff B.W. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. Journal of Neurochemistry 2002, 82:736-754.
21. Fisk J.D., Rockwood K. Outcomes of incident mild cognitive impairment in relation to case definition. Journal of Neurology, Neurosurgery, and Psychiatry 2005, 76:1175-1177.
22. Foy C.M., Daly E.M., Glover A., O'Gorman R., Simmons A., Murphy D.G., Lovestone S. Hippocampal proton MR spectroscopy in early Alzheimer's disease and mild cognitive impairment. Brain Topography 2011, 24:316-322.
23. Franczak M., Prost R.W., Antuono P.G., Mark L.P., Jones J.L., Ulmer J.L. Proton magnetic resonance spectroscopy of the hippocampus in patients with mild cognitive impairment: a pilot study. Journal of Computer Assisted Tomography 2007, 31:666-670.
24. Garcia Santos J.M., Gavrila D., Antunez C., Tormo M.J., Salmeron D., Carles R., Jimenez Veiga J., Parrilla G., Torres del Rio S., Fortuna L., Navarro C. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. Dementia and Geriatric Cognitive Disorders 2008, 26:15-25.
25. Griffith H.R., Hollander J.A.D., Okonkwo O., Evanochko W.T., Harrell L.E., Zamrini E.Y., Brockington J.C., Marson D.C. Executive function is associated with brain proton magnetic resonance spectroscopy in amnestic mild cognitive impairment. Journal of Clinical and Experimental Neuropsychology: Official Journal of the International Neuropsychological Society 2007, 29:599-609.
26. Griffith H.R., den Hollander J.A., Stewart C.C., Evanochko W.T., Buchthal S.D., Harrell L.E., Zamrini E.Y., Brockington J.C., Marson D.C. Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease. NMR in Biomedicine 2007, 20:709-716.
27. Griffith H.R., Okonkwo O.C., den Hollander J.A., Belue K., Copeland J., Harrell L.E., Brockington J.C., Clark D.G., Marson D.C. Brain metabolic correlates of decision making in amnestic mild cognitive impairment. Neuropsychology, Development, and Cognition. Section B, Aging, Neuropsychology and Cognition 2010, 17:492-504.
28. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002, 21:1539-1558.
29. Ikonomovic M.D., Mufson E.J., Wuu J., Cochran E.J., Bennett D.A., DeKosky S.T. Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. Journal of Alzheimer's Disease: JAD 2003, 5:39-48.
30. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Wuu J., Mathis C.A., Scheff S.W., Mufson E.J., DeKosky S.T. Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. Neurology 2011, 77:39-47.
31. Jack C.R., Wiste H.J., Vemuri P., Weigand S.D., Senjem M.L., Zeng G., Bernstein M.A., Gunter J.L., Pankratz V.S., Aisen P.S., Weiner M.W., Petersen R.C., Shaw L.M., Trojanowski J.Q., Knopman D.S. Alzheimer's disease neuroimaging initiative, 2010. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010, 133:3336-3348.
32. Jessen F., Traeber F., Freymann K., Maier W., Schild H.H., Block W. Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 2006, 67:528-530.
33. Jessen F., Gur O., Block W., Ende G., Frolich L., Hammen T., Wiltfang J., Kucinski T., Jahn H., Heun R., Maier W., Kolsch H., Kornhuber J., Traber F. A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI. Neurology 2009, 72:1735-1740.
34. Jicha G.A., Parisi J.E., Dickson D.W., Johnson K., Cha R., Ivnik R.J., Tangalos E.G., Boeve B.F., Knopman D.S., Braak H., Petersen R.C. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Archives of Neurology 2006, 63:674-681.
35. Kantarci K., Jack C.R., Xu Y.C., Campeau N.G., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Kokmen E., Tangalos E.G., Petersen R.C. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 2000, 55:210-217.
36. Kantarci K., Smith G.E., Ivnik R.J., Petersen R.C., Boeve B.F., Knopman D.S., Tangalos E.G., Jack C.R. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. Journal of the International Neuropsychological Society: JINS 2002, 8:934-942.
37. Kantarci K., Xu Y., Shiung M.M., O'Brien P.C., Cha R.H., Smith G.E., Ivnik R.J., Boeve B.F., Edland S.D., Kokmen E., Tangalos E.G., Petersen R.C., Jack C.R. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2002, 14:198-207.
38. Kantarci K., Reynolds G., Petersen R.C., Boeve B.F., Knopman D.S., Edland S.D., Smith G.E., Ivnik R.J., Tangalos E.G., Jack C.R. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease, Comparison of 1.5 and 3T. American Journal of Neuroradiology 2003, 24:843-849.
39. Kantarci K., Weigand S.D., Petersen R.C., Boeve B.F., Knopman D.S., Gunter J., Reyes D., Shiung M., O'Brien P.C., Smith G.E., Ivnik R.J., Tangalos E.G., Jack C.R. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging 2007, 28:1330-1339.
40. Kantarci K. 1H magnetic resonance spectroscopy in dementia. The British Journal of Radiology 2007, 80(Spec No 2):S146-S152.
41. Kantarci K., Petersen R.C., Przybelski S.A., Weigand S.D., Shiung M.M., Whitwell J.L., Negash S., Ivnik R.J., Boeve B.F., Knopman D.S., Smith G.E., Jack C.R. Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Archives of Neurology 2008, 65:1621-1628.
42. Kantarci K., Knopman D.S., Dickson D.W., Parisi J.E., Whitwell J.L., Weigand S.D., Josephs K.A., Boeve B.F., Petersen R.C., Jack C.R. Alzheimer disease: postmortem neuropathologic correlates of antemortem H-1 MR Spectroscopy metabolite measurements. Radiology 2008, 248:210-220.
43. Kantarci K., Weigand S.D., Przybelski S.A., Shiung M.M., Whitwell J.L., Negash S., Knopman D.S., Boeve B.F., O'Brien P.C., Petersen R.C., Jack C.R. Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. Neurology 2009, 72:1519-1525.
44. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. Journal of Neural Transmission 2000, 107:1027-1063.
45. Kreis R., Ernst T., Ross B.D. Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 1993, 30:424-437.
46. Krishnan K.R., Charles H.C., Doraiswamy P.M., Mintzer J., Weisler R., Yu X., Perdomo C., Ieni J.R., Rogers S. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. The American Journal of Psychiatry 2003, 160:2003-2011.
47. Li B.S., Wang H., Gonen O. Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magnetic Resonance Imaging 2003, 21:923-928.
48. Li X., Shao X., Wang N., Wang T., Chen G., Zhou H. Correlation of auditory event-related potentials and magnetic resonance spectroscopy measures in mild cognitive impairment. Brain Research 2010, 1346:204-212.
49. Lim T.S., Hong Y.H., Lee H.Y., Choi J.Y., Kim H.S., Moon S.Y. Metabolite investigation in both anterior and posterior cingulate gyri in Alzheimer's disease spectrum using 3-Tesla MR spectroscopy. Dementia and Geriatric Cognitive Disorders 2012, 33:149-155.
50. Lim T.S., Hong Y.H., Choi J.Y., Kim H.S., Moon S.Y. Functional investigation of bilateral posterior cingulate gyri using multivoxel MR spectroscopy. European Neurology 2012, 67:279-286.
51. Markesbery W.R. Neuropathologic alterations in mild cognitive impairment: a review. Journal of Alzheimer's Disease: JAD 2010, 19:221-228.
52. Matthews F.E., Stephan B.C., McKeith I.G., Bond J., Brayne C. Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society 2008, 56:1424-1433. Medical Research Council Cognitive Function and Ageing Study.
53. Metastasio A., Rinaldi P., Tarducci R., Mariani E., Feliziani F.T., Cherubini A., Pelliccioli G.P., Gobbi G., Senin U., Mecocci P. Conversion of MCI to dementia: role of proton magnetic resonance spectroscopy. Neurobiology of Aging 2006, 27:926-932.
54. Miller B.L., Chang L., Booth R., Ernst T., Cornford M., Nikas D., McBride D., Jenden D.J. In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sciences 1996, 58:1929-1935.
55. Modrego P.J., Fayed N., Pina M.A. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. The American Journal of Psychiatry 2005, 162:667-675.
56. Modrego P.J., Pina M.A., Fayed N., Diaz M. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. CNS Drugs 2006, 20:867-877.
57. Modrego P.J., Fayed N., Sarasa M. Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort study. BMJ Open 2011, 1. 10.1136/bmjopen-2010-000007.
58. Moffett J.R., Ross B., Arun P., Madhavarao C.N., Namboodiri A.M. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Progress in Neurobiology 2007, 81:89-131.
59. Mountford C.E., Stanwell P., Lin A., Ramadan S., Ross B. Neurospectroscopy: the past, present and future. Chemical Reviews 2010, 110:3060-3086.
60. Olson B.L., Holshouser B.A., Britt W., Mueller C., Baqai W., Patra S., Petersen F., Kirsch W.M. Longitudinal metabolic and cognitive changes in mild cognitive impairment patients. Alzheimer Disease and Associated Disorders 2008, 22:269-277.
61. Palmer K., Backman L., Winblad B., Fratiglioni L. Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry 2008, 16:603-611.
62. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 1999, 56:303-308.
63. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., Winblad B. Current concepts in mild cognitive impairment. Archives of Neurology 2001, 58:1985-1992.
64. Petersen R.C., Roberts R.O., Knopman D.S., Boeve B.F., Geda Y.E., Ivnik R.J., Smith G.E., Jack C.R. Mild cognitive impairment: ten years later. Archives of Neurology 2009, 66:1447-1455.
65. Pilatus U., Lais C., Rochmont A.d.M.d., Kratzsch T., Frolich L., Maurer K., Zanella F.E., Lanfermann H., Pantel J. Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy. Psychiatry Research: Neuroimaging 2009, 173:1-7.
66. Pouwels P.J., Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 1998, 39:53-60.
67. Quigley H., Colloby S.J., O'Brien J.T. PET imaging of brain amyloid in dementia: a review. International Journal of Geriatric Psychiatry 2011, 26:991-999.
68. Rabinovici G.D., Jagust W.J. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behavioural Neurology 2009, 21:117-128.
69. Rami L., Gomez-Anson B., Sanchez-Valle R., Bosch B., Monte G.C., Llado A., Molinuevo J.L. Longitudinal study of amnesic patients at high risk for Alzheimer's disease: clinical, neuropsychological and magnetic resonance spectroscopy features. Dementia and Geriatric Cognitive Disorders 2007, 24:402-410.
70. Rami L., Gomez-Anson B., Bosch B., Sanchez-Valle R., Monte G.C., Villar A., Molinuevo J.L. Cortical brain metabolism as measured by proton spectroscopy is related to memory performance in patients with amnestic mild cognitive impairment and Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2007, 24:274-279.
71. Rami L., Caprile C., Gomez-Anson B., Sanchez-Valle R., Monte G.C., Bosch B., Molinuevo J.L. Naming is associated with left temporal pole metabolite levels in neurodegenerative diseases. Dementia and Geriatric Cognitive Disorders 2008, 25:212-217.
72. Ritchie K. Mild cognitive impairment: an epidemiological perspective. Dialogues in Clinical Neuroscience 2004, 6:401-408.
73. Rupsingh R., Borrie M., Smith M., Wells J.L., Bartha R. Reduced hippocampal glutamate in Alzheimer disease. Neurobiology of Aging 2011, 32:802-810.
74. Schonknecht P., Pantel J., Kruse A., Schroder J. Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young-old subjects. The American Journal of Psychiatry 2005, 162:2071-2077.
75. Senn S.J. Overstating the evidence: double counting in meta-analysis and related problems. BMC Medical Research Methodology 2009, 9. 10.1186/1471-2288-9-10.
76. Seo S.W., Lee J.H., Jang S.M., Kim S.T., Chin J., Kim G.H., Kim J.H., Roh J.H., Kim M.J., Kim S.H., Na D.L. Neurochemical alterations of the entorhinal cortex in amnestic mild cognitive impairment (aMCI): a three-year follow-up study. Archives of Gerontology and Geriatric 2012, 54:192-196.
77. Shiino A., Watanabe T., Shirakashi Y., Kotani E., Yoshimura M., Morikawa S., Inubushi T., Akiguchi I. The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2012, 32:805-815.
78. Siger M., Schuff N., Zhu X., Miller B.L., Weiner M.W. Regional myo-inositol concentration in mild cognitive impairment using 1H magnetic resonance spectroscopic imaging. Alzheimer Disease and Associated Disorders 2009, 23:57-62.
79. Signoretti S., Marmarou A., Tavazzi B., Lazzarino G., Beaumont A., Vagnozzi R. N-Acetylaspartate reduction as a measure of injury severity and mitochondrial dysfunction following diffuse traumatic brain injury. Journal of Neurotrauma 2001, 18:977-991.
80. Solfrizzi V., Panza F., Colacicco A.M., D'Introno A., Capurso C., Torres F., Grigoletto F., Maggi S., Del Parigi A., Reiman E.M., Caselli R.J., Scafato E., Farchi G., Capurso A. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004, 63:1882-1891. Italian Longitudinal Study on Aging Working Group.
81. Storandt M., Grant E.A., Miller J.P., Morris J.C. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 2006, 67:467-473.
82. Walecki J., Barcikowska M., Cwikla J.B., Gabryelewicz T. N-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI). Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 2011, 17:MT105-MT111.
83. Wang T., Xiao S., Li X., Ding B., Ling H., Chen K., Fang Y. Using proton magnetic resonance spectroscopy to identify mild cognitive impairment. International Psychogeriatrics 2012, 24:19-27.
84. Wang X.C., Du X.X., Tian Q., Wang J.Z. Correlation between choline signal intensity and acetylcholine level in different brain regions of rat. Neurochemical Research 2008, 33(5):814-819.
85. Wang Z., Zhao C., Yu L., Zhou W., Li K. Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease. Acta Radiologica 2009, 50:312-319.
86. Ward A., Arrighi H.M., Michels S., Cedarbaum J.M. Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimer's & Dementia: the Journal of the Alzheimer's Association 2012, 8:14-21.
87. Watanabe T., Shiino A., Akiguchi I. Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease. Dementia and Geriatric Cognitive Disorders 2008, 26:89-100.
88. Watanabe T., Shiino A., Akiguchi I. Absolute quantification in proton magnetic resonance spectroscopy is useful to differentiate amnesic mild cognitive impairment from Alzheimer's disease and healthy aging. Dementia and Geriatric Cognitive Disorders 2010, 30:71-77.
89. Watanabe T., Shiino A., Akiguchi I. Hippocampal metabolites and memory performances in patients with amnestic mild cognitive impairment and Alzheimer's disease. Neurobiology of Learning and Memory 2012, 97:289-293.
90. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., Nordberg A., Backman L., Albert M., Almkvist O., Arai H., Basun H., Blennow K., de Leon M., DeCarli C., Erkinjuntti T., Giacobini E., Graff C., Hardy J., Jack C., Jorm A., Ritchie K., van Duijn C., Visser P., Petersen R.C. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine 2004, 256:240-246.
91. Yang Z.X., Huo S.S., Cheng X.F., Xu Z.F., Cao Z., Zeng J.X., Xiao Y.Y., You K.Z., Chen W., Liu Y.Y., Wu R.H. Quantitative multivoxel proton MR spectroscopy study of brain metabolites in patients with amnestic mild cognitive impairment. A pilot study. Neuroradiology 2012, 54:451-458.
92. Zhang B., Li M., Sun Z.Z., Zhu B., Yuan L., Wang Y., Xu Y. Evaluation of functional MRI markers in mild cognitive impairment. Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia 2009, 16:635-641.
93. Zhu H., Barker P.B. MR spectroscopy and spectroscopic imaging of the brain. Methods in Molecular Biology 2011, 711:203-226.
94. Zimny A., Szewczyk P., Trypka E., Wojtynska R., Noga L., Leszek J., Sasiadek M. Multimodal imaging in diagnosis of Alzheimer's disease and amnestic mild cognitive impairment: value of magnetic resonance spectroscopy, perfusion, and diffusion tensor imaging of the posterior cingulate region. Journal of Alzheimer's Disease: JAD 2011, 27:591-601.